# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Sonnet discovered and characterized a modified version of Interleukin-18 (IL-18Binding Protein Resistant or IL-18BPR) that exhi...
Chardan Capital analyst Keay Nakae maintains Sonnet BioTherapeutics (NASDAQ:SONN) with a Buy and maintains $30 price target.